XML 23 R6.htm IDEA: XBRL DOCUMENT v3.25.4
Consolidated Statements of Changes in Stockholders’ Equity - USD ($)
Preferred Stock
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Total Citius Pharmaceuticals, Inc. Stockholders’ Equity
Non- Controlling Interest
Total
Balance at Sep. 30, 2023 $ 6,354 $ 253,056,133 $ (162,231,379) $ 90,831,108 $ 600,380 $ 91,431,488
Balance (in Shares) at Sep. 30, 2023   6,354,371          
Issuance of common stock for services $ 15 284,161 284,176 284,176
Issuance of common stock for services (in Shares)   15,479          
Issuance of common stock upon exercise of stock options $ 2 (2)
Issuance of common stock upon exercise of stock options (in Shares)   2,082          
Sale of common stock, net of costs $ 876 13,802,808 13,803,684 13,803,684
Sale of common stock, net of costs (in Shares)   875,311          
Stock-based compensation expense 11,839,678 11,839,678 11,839,678
Merger, net of transaction costs of $2,358,780 (3,831,357) (3,831,357) (3,831,357)
Minority interest from Merger (3,711,000) (3,711,000) 3,711,000
Net loss (39,425,839) (39,425,839) (39,425,839)
Net loss attributable to noncontrolling interest 287,000 287,000 (287,000)
Balance at Sep. 30, 2024 $ 7,247 271,440,421 (201,370,218) 70,077,450 4,024,380 74,101,830
Balance (in Shares) at Sep. 30, 2024   7,247,243          
November 2024 sale of common stock, net of costs of $425,949 $ 480 2,573,571 2,574,051 2,574,051
November 2024 sale of common stock, net of costs of $425,949 (in Shares)   480,000          
January 2025 sale of common stock, net of costs of $342,833 $ 744 2,656,423 2,657,167 2,657,167
January 2025 sale of common stock, net of costs of $342,833 (in Shares)   743,496          
April 2025 sale of common stock and pre-funded warrants, net of costs of $256,116 $ 465 1,743,292 1,743,757 1,743,757
April 2025 sale of common stock and pre-funded warrants, net of costs of $256,116 (in Shares)   465,000          
June 2025 sale of common stock and pre-funded warrants, net of costs of $571,126 $ 540 5,430,296 5,430,836 5,430,836
June 2025 sale of common stock and pre-funded warrants, net of costs of $571,126 (in Shares)   540,000          
July 2025 sale of common stock by Citius Oncology, net of costs of $1,453,012 3,770,278 3,770,278 (3,776,710) 7,546,988
September 2025 sale of common stock by Citius Oncology, net of costs of $1,380,146 4,090,493 4,090,493 (3,529,361) 7,619,854
Issuance of common stock upon exercise of pre-funded warrants $ 5,654 (5,088) 566 566
Issuance of common stock upon exercise of pre-funded warrants (in Shares)   5,654,131          
Sales of common stock under at the market offering agreement, net of costs $ 2,918 4,727,011 4,729,929 4,729,929
Sales of common stock under at the market offering agreement, net of costs (in Shares)   2,917,874          
Sale of Series A preferred stock 1 100 100 100
Redemption of Series A preferred stock (1) (100) (100) (100)
Issuance of common stock for services $ 20 26,580 26,600 26,600
Issuance of common stock for services (in Shares)   20,000          
Stock-based compensation expense 9,882,962 9,882,962 953,329 10,836,291
Net loss (39,740,269) (39,740,269) (39,740,269)
Net loss attributable to noncontrolling interest 2,306,358 2,306,358 (2,306,358)
Balance at Sep. 30, 2025 $ 18,068 $ 306,336,239 $ (238,804,129) $ 67,550,178 $ 9,977,422 $ 77,527,600
Balance (in Shares) at Sep. 30, 2025   18,067,744